Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study

Antiviral Research

Volumn 92, Issue 1, 2011, Pages 90-95

  Si Ahmed, Si Nafa ^a,b,c   Pradat, Pierre ^a,b,c   Zoutendijk, Roeland ^d   Buti, Maria ^e,f   Mallet, Vincent ^g   Cruiziat, Claire ^a   Deterding, Katja ^h   Dumortier, Jérôme ^a,b,c   Bailly, François ^a,b,c   Esteban, Rafael ^e,f   Wedemeyer, Heiner ^h   Janssen, Harry L ^d   Zoulim, Fabien ^a,b,c,i  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Inst universitaire de France ^*  (France)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

Chronic hepatitis b; Combination therapy; Emtricitabine; Tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS B; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; EUROPE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

HEPATITIS B VIRUS;

EID: 80052850404     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.003     Document Type: Article

References (32)

1. Ahmed S.N.S., Tavan D., Pichoud C., Berby F., Stuyver L., Johnson M., Merle P., Abidi H., Trepo C., Zoulim F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32:1078-1088.
2. Anonymous Emtricitabine/tenofovir disoproxil fumarate. Drugs R D 2004, 5:160-161.
3. Berg T., Marcellin P., Moeller B., Trinh H.N., Chan S., Suarez E., Snow-Lampart A., Peschell K.J., Borroto-Esoda K., Hirsch K.R., Frederick D. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxil: final week 168 results. Hepatology 2010, 52(Suppl):387A.
4. Berg T., Marcellin P., Zoulim F., Moller B., Trinh H., Chan S., Suarez E., Lavocat F., Snow-Lampart A., Frederick D., Sorbel J., Borroto-Esoda K., Oldach D., Rousseau F. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010, 139:1207-1217.
5. EASL EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50:227-242.
6. Fontana R.J., Hann H.W., Perrillo R.P., Vierling J.M., Wright T., Rakela J., Anschuetz G., Davis R., Gardner S.D., Brown N.A. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123:719-727.
7. Gish R.G., Leung N.W., Wright T.L., Trinh H., Lang W., Kessler H.A., Fang L., Wang L.H., Delehanty J., Rigney A., Mondou E., Snow A., Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 2002, 46:1734-1740.
8. Gish R.G., Trinh H., Leung N., Chan F.K., Fried M.W., Wright T.L., Wang C., Anderson J., Mondou E., Snow A., Sorbel J., Rousseau F., Corey L. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. 2005, 43:60-66.
9. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., Germanidis G., Lee S.S., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas O.O., Shiffman M.L., Trinh H., Gurel S., Snow-Lampart A., Borroto-Esoda K., Mondou E., Anderson J., Sorbel J., Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
10. Jenh A.M., Pham P.A. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev. Anti. Infect. Ther. 2010, 8:1079-1092.
11. Labarga P., Barreiro P., Martin-Carbonero L., Rodriguez-Novoa S., Solera C., Medrano J., Rivas P., Albalater M., Blanco F., Moreno V., Vispo E., Soriano V. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009, 23:689-696.
12. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N.V., Di Bisceglie A.M., Zeuzem S., Moon Y.M., Goodman Z., Chao G., Constance B.F., Brown N.A. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357:2576-2588.
13. Lampertico P., Viganò M., Soffredini R., Facchetti F., Minola E., Suter F., Zaltron S., Vavassori A., Gubertini G.A., Magni C., Testa A., Antonucci G., Pinzello G., Vinci M., Fatta E., Fargion S., Del Poggio P., Coco B., Brunetto M.R., Andreoletti M., Santantonio T., Colloredo G., Fagiuoli S., Colombo A.E., Maldini F.F., Pozzi M., Terreni N.M., Quagliuolo M., Lunghi G., Colombo M. Maintained long-term suppression of HBV replication in NUC-naive patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience. Hepatology 2010, 52(Suppl.):514A.
14. Lampertico P., Viganò M., Yurdaydin C., Idilman R., Buti M., Esteban R., Papatheodoridis G.V., Pinzello G., Vinci M., Minola E., Suter F., Del Poggio P., Andreoletti M., Fagiuoli S., Colombo A.E., Salmi A., Santantonio T., Magni C., Gubertini G.A., Maldini F.F., Terreni N.M., Facchetti F., Soffredini R., Colombo M. Effectiveness ans safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B. Hepatology 2010, 52(Suppl.):503A.
15. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11:97-107.
16. Levrero M., Cimino L., Lampertico P., Viganò M., Gaeta G.B., Brancaccio G., Sagnelli E., Messina V., Raimondo G., Marzano A., Fagiuoli S., Niro G.A., Santantonio T., Di Marco V., Mazzella G., Di Costanzo G.G., Angelico M., Pierconti S., Sava' C.C. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OPTIB Italian multicenter prospective open label study. Hepatology 2010, 52(Suppl):389A.
17. Liaw Y.-F., Sheen I.S., Lee C.-M., Akarca U.S., Papatheodoridis G.V., Suet-Hing Wong F., Chang T.-T., Horban A., Wang C., Kwan P., Buti M., Prieto M., Berg T., Kitrinos K., Peschell K., Mondou E., Frederick D., Rousseau F., Schiff E.R. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
18. Liaw Y.F., Leung N., Guan R., Lau G.K., Merican I., McCaughan G., Gane E., Kao J.H., Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005, 25:472-489.
19. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351:1521-1531.
20. Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., Lee S.S., Chan S., Shiffman M.L., Washington M.K., Rigney A., Anderson J., Mondou E., Snow A., Sorbel J., Guan R., Rousseau F. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Int. Med. 2006, 166:49-56.
21. Locarnini S., Hatzakis A., Heathcote J., Keeffe E.B., Liang T.J., Mutimer D., Pawlotsky J.M., Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 2004, 9:679-693.
22. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., Liaw Y.F., Mizokami M., Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
23. Mommeja-Marin H., Mondou E., Blum M.R., Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003, 37:1309-1319.
24. Si Ahmed S.N., Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Rev. Anti. Infect. Ther. 2009, 7:309-320.
25. Snow-Lampart A., Kitrinos K.M., Chappell B.J., Myrick F.T., Schawalder J.C., Heathcote J., Marcellin P., Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate (TDF) detected following up to 192weeks of treatment in subjects monoinfected with chronic hepatitis B virus. Hepatology 2010, 52(Suppl.):977A.
26. Snow-Lampart A., Chappell B., Curtis M., Zhu Y., Myrick F., Schawalder J., Kitrinos K., Svarovskaia E.S., Miller M.D., Sorbel J., Heathcote J., Marcellin P., Borroto-Esoda K. No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
27. Sorrell M.F., Belongia E.A., Costa J., Gareen I.F., Grem J.L., Inadomi J.M., Kern E.R., McHugh J.A., Petersen G.M., Rein M.F., Strader D.B., Trotter H.T. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Int. Med. 2009, 150:104-110.
28. Woodward C.L., Hall A.M., Williams I.G., Madge S., Copas A., Nair D., Edwards S.G., Johnson M.A., Connolly J.O. Tenofovir-associated renal and bone toxicity. HIV Med. 2009, 10:482-487.
29. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
30. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 2004, 64:1-15.
31. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.
32. Zoutendijk R., Reijnders J.G., Brown A., Zoulim F., Mutimer D., Deterding K., Petersen J., Hofmann W.P., Buti M., Santantonio T., van Bömmel F., Pradat P., Oo Y., Luctgehetmann M., Berg T., Hansen B.E., Wedemeyer H., Janssen H.L. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of native patients with a partial virological response. Hepatology 2010, for the VIRGIL Surveillance Study Group, [Epub ahead of print]. 10.1002/hep.24406.